Huatai-PB CSI Chinese Medicine ETF(561510.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Huatai-PB CSI Chinese Medicine ETF
561510.SH
News
View More

John Lee: Signed two medical cooperation agreements with the mainland to promote the development of traditional Chinese medicine and cancer prevention and treatment

Chief Executive John Lee met with Lei Haichao, Director of the National Health Commission, to sign the "Traditional Chinese Medicine Cooperation Agreement" and the "Cancer Prevention and Control Cooperation Framework Agreement." John Lee stated that the SAR government values cooperation with the country, promotes high-quality development of healthcare in Hong Kong, and is committed to making Hong Kong a bridgehead for traditional Chinese medicine to reach the world, as well as enhancing cancer services. Hong Kong will continue to promote medical cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area, supporting the country's "Healthy China" strategy

AASTOCKS·
SH
561510
-0.10%
AASTOCKS·
SH
561510
-0.10%

Mainland National Health and Wellness Work Conference: Optimize Fertility Support Policies to Stabilize the Scale of Newborn Population

The National Health and Wellness Work Conference in Mainland China was held in Beijing from January 5 to 6, emphasizing key tasks for 2026, including strengthening the prevention and control of major diseases, optimizing fertility support policies, promoting a positive view on marriage and childbirth, advancing inclusive childcare development, distributing childcare subsidies, optimizing maternal and child services, and promoting the comprehensive development of traditional Chinese medicine services

AASTOCKS·
SH
561510
-0.10%
AASTOCKS·
SH
561510
-0.10%

The Health Department promotes a graded diversion mechanism for the approval of traditional Chinese medicine registration applications

The Department of Health announced that starting from January 1, 2026, it will pilot the "Tiered and Streamlined Review and Approval Arrangement for the Registration Applications of Traditional Chinese Medicine," adding two levels: "Innovative Drugs" and "Designated Priority Products," to expedite the processing of registration applications. The approval time for innovative drugs is 120 working days, while designated priority products will take 150 working days. The new mechanism aims to accelerate the approval speed, help enterprises plan their business and resources more effectively, and promote Hong Kong as an international hub for medical innovation

AASTOCKS·
SH
562390
-0.10%
SH
561510
-0.10%
AASTOCKS·
SH
562390
-0.10%
SH
561510
-0.10%

The 15th Five-Year Plan recommendations released: Accelerate the construction of a Healthy China

The released 14th Five-Year Plan recommendations emphasize the implementation of a health-first development strategy, enhancing public health capabilities, strengthening the disease control system, improving the collaborative development mechanism of medical care, medical insurance, and pharmaceuticals, and promoting hierarchical diagnosis and treatment. It is recommended to deepen the reform of public hospitals, optimize the layout of medical institutions, advance the digitalization of national health, strengthen chronic disease prevention and control as well as emergency response capabilities, and support innovation in traditional Chinese medicine and mental health services

Zhitong·
SH
561510
-0.10%
Zhitong·
SH
561510
-0.10%

Research shows: Traditional Chinese medicine provides new options to combat certain types of "superbugs."

Research shows that the traditional Chinese medicine compound Xinjia Dayuan Powder demonstrates significant advantages in treating multidrug-resistant Gram-negative bacterial pneumonia, providing a new option for combating "superbugs." After two years of clinical trials, the research results have been published in the international journal "Phytomedicine." Experts point out that this discovery offers patients an auxiliary treatment option and further proves the unique value of traditional Chinese medicine in treating difficult diseases

Zhitong·
SH
562390
-0.10%
SH
561510
-0.10%
Zhitong·
SH
562390
-0.10%
SH
561510
-0.10%
© 2026 Longbridge｜Disclaimer